Search
Olcegepant
go.drugbank.com/drugs/DB04869InvestigationalOlcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks
Petrelintide
go.drugbank.com/drugs/DB19442InvestigationalPetrelintide is under investigation in clinical trial NCT06662539 (Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities).
Afimoxifene
go.drugbank.com/drugs/DB04468InvestigationalIt is being developed by Ascent Therapeutics. … Afimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia.
OTL-201
go.drugbank.com/drugs/DB17652ExperimentalOTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). … It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.[L45973]
Serine/threonine-protein kinase SIK2
go.drugbank.com/bio_entities/BE0009538TargetHumansSerine/threonine-protein kinase that plays a role in many biological processes such as fatty acid oxidation, autophagy, immune response or glucose metabolism (PubMed:23322770, PubMed:26983400). Phosphorylates 'Ser-794' of IRS1 in insulin...
Synonyms: Salt-inducible kinase 2Bordetella pertussis toxoid antigen (glutaraldehyde inactivated)
go.drugbank.com/drugs/DB10787ApprovedInvestigationalMixtures: ADACEL SUSPENSION FOR INJECTIONHaemagglutinin-strain A(H3N2)
go.drugbank.com/drugs/DB15475ApprovedInvestigationalMixtures: Influvac Suspension for InjectionHaemagglutinin-strain A(H1N1)
go.drugbank.com/drugs/DB15476ApprovedInvestigationalMixtures: Influvac Suspension for InjectionLumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnOn August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver
Lesopitron
go.drugbank.com/drugs/DB04970ExperimentalLesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.